Micaily Ida, Johnson Jennifer, Argiris Athanassios
Department of Medical Oncology, Thomas Jefferson University, 1025 Walnut Street, Suite 700, Philadelphia, PA USA.
Cancers Head Neck. 2020 Apr 6;5:5. doi: 10.1186/s41199-020-00051-9. eCollection 2020.
Angiogenesis is an integral aspect of the growth and proliferation of solid tumors, including head and neck squamous cell carcinoma (HNSCC), and has potential implications in prognosis and treatment of both localized and recurrent/metastatic HNSCC. Therefore, there has been a significant interest in utilizing anti-angiogenic agents either alone or in combination with currently approved and emerging therapies. A phase III randomized trial (E1305) of chemotherapy with or without bevacizumab in the first-line treatment of recurrent/metastatic HNSCC showed an increased response rate and longer progression-free survival but fell short in demonstrating a statistically significant improved survival with bevacizumab. Moreover, toxicity, especially bleeding, was increased. Nevertheless, the study of other anti-angiogenic agents and novel combinations with other therapies, including immunotherapy, remains of interest. Several clinical trials are currently underway.
血管生成是实体瘤生长和增殖的一个重要方面，包括头颈部鳞状细胞癌（HNSCC），并且对局限性和复发/转移性HNSCC的预后和治疗具有潜在影响。因此，单独或与目前已获批及新出现的疗法联合使用抗血管生成药物引起了人们极大的兴趣。一项关于在复发/转移性HNSCC一线治疗中使用或不使用贝伐单抗进行化疗的III期随机试验（E1305）显示，缓解率有所提高，无进展生存期延长，但在证明贝伐单抗能使生存期有统计学意义的显著改善方面未达预期。此外，毒性尤其是出血有所增加。尽管如此，对其他抗血管生成药物以及与包括免疫疗法在内的其他疗法的新型联合用药的研究仍备受关注。目前正在进行多项临床试验。
